Omeros

Omeros discovers, develops, and commercializes small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system, immunologic disorders, cancers, and addictive/compulsive disorders.

Gregory A. Demopulos

Chairman and CEO

1 past transactions

Nura

Acquisition in 2006
Nura, Inc. is focused on discovering and developing pharmaceuticals aimed at treating neurodegenerative diseases and behavioral disorders. The company specializes in therapeutics that target G Protein-coupled receptors (GPCR) and phosphodiesterase (PDE) enzymes expressed in the brain. Nura’s research includes programs for conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia, depression, anxiety, obesity, and addiction, as well as attention-deficit hyperactivity disorder and pain. Through its innovative approach, Nura aims to address significant unmet medical needs in these areas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.